AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ALTERITY THERAPEUTICS LTD

0.008

+0.00114.29%

Volume:5.35M

Turnover:42.81K

Market Cap:73.02M

PE:-2.02

High:0.008

Open:0.008

Low:0.008

Close:0.007

Loading ...

Overview Company News Filings

Gold rips as Genesis’ growing reserves point to early arrival at 400,000 oz milestone

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Fidelity Spotlights 8-Year-Old Bullish Bitcoin Move From Japan

BRIEF-Alterity Therapeutics Completes Last Patient Visit In ATH434-202 Open-Label Phase 2 Trial In Multiple System Atrophy

Alterity Therapeutics Ltd: Topline Data Expected Mid-Year 2025

THOMSON REUTERS

Alterity Therapeutics Completes Last Patient Visit in Ath434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

THOMSON REUTERS

Alterity Completes Neurogenerative Disease Trial

MT Newswires Live

Justin Sun Reveals Rules of Making Memes on Tron: Details

XRP Flashes 102% Liquidation Imbalance as Price Rebound Fails

Coinbase to Remove Three Crypto Assets? Reason Behind It

3 Promising ASX Penny Stocks With Market Caps Over A$20M

Simply Wall St.

BRIEF-Alterity Therapeutics Posts HY Net Loss After Tax Attributable A$7.2 Million

Alterity Therapeutics - Hy Net Loss After Tax Attributable a$7.2 Mln

THOMSON REUTERS

Alterity Therapeutics Ltd-Proposed Issue of Securities - Ath

THOMSON REUTERS

Alterity Therapeutics Raises AU$40 Million via Placement

MT Newswires Live

Alterity Therapeutics Raises a$40.0 Million in Placement

THOMSON REUTERS

Alterity Therapeutics Ltd - Proceeds to Fund Ongoing Clinical Development for Ath434

THOMSON REUTERS

BUZZ-Australia's Alterity Therapeutics falls on discounted placement

BRIEF-Alterity Therapeutics Raises A$40M To Advance Ath434 Development In MSA

Alterity Therapeutics - Alterity Raises a$40M to Advance Ath434 Development in MSA

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATH.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","market":"AU","secType":"STK","nameCN":"ALTERITY THERAPEUTICS LTD","latestPrice":0.008,"timestamp":1745296902122,"preClose":0.007,"halted":0,"volume":5351033,"delay":0,"nameEN":"ALTERITY THERAPEUTICS LTD","floatShares":4795812943,"shares":9127370686,"eps":-0.003967,"marketStatus":"Trading","change":0.001,"latestTime":"04-22 14:44:43 AEST","open":0.008,"high":0.008,"low":0.008,"amount":42808,"amplitude":0,"askPrice":0.009,"askSize":9748464,"bidPrice":0.008,"bidSize":7275027,"shortable":3,"etf":0,"ttmEps":-0.003967,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745301600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.007,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.644124,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","floatShares":4795812943,"roa":"-78.37%","roe":"-155.77%","lyrEps":-0.00524,"volumeRatio":0.644124,"shares":9127370686,"dividePrice":0,"high":0.008,"amplitude":0,"preClose":0.007,"low":0.008,"week52Low":0.002,"pbRate":"9.38","psRate":"19.61","week52High":0.019,"institutionHeld":0,"latestPrice":0.008,"committee":-0.145296,"eps":-0.003967,"divideRate":0,"volume":5351033,"delay":0,"ttmEps":-0.003967,"open":0.008,"prevYearClose":0.008,"prevWeekClose":0.007,"prevMonthClose":0.009,"prevQuarterClose":0.009,"fiveDayClose":0.008,"twentyDayClose":0.009,"sixtyDayClose":0.009},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATH.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526395520","title":"Gold rips as Genesis’ growing reserves point to early arrival at 400,000 oz milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2526395520","media":"LiveWire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526395520?lang=en_us&edition=fundamental","pubTime":"2025-04-11 06:39","pubTimestamp":1744324768,"startTime":"0","endTime":"0","summary":"President Trump’s helter-skelter approach to tariff negotiations has been a good thing for the gold price.It is back in record territory , not because of the normal drivers of inflation expectations, US dollar moves or recession fears, but because no one knows what Trump will do next.While it’s a nervous wait for his next tweet, it can be said that gold is also benefitting from the 90-day reprieve coming with a massive sting in the tail in that fellow super power China was hit with higher tariffs still.That probably more anything has been driving investment into gold – the safest of havens in a world not too sure where Trump is taking us one day to the next.So as the World Gold council noted this week in polite terms, the environment remains supportive for further gains in the gold price. It also noted that gold backed ETFs attracted $US8.6bn in March.Gold’s move back to all-time highs in Thursday’s monster relief rally in equity markets meant ASX gold equities had a particularly good ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/gold-rips-as-genesis-growing-reserves-point-to-early-arrival-at-400-000-oz-milestone","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/gold-rips-as-genesis-growing-reserves-point-to-early-arrival-at-400-000-oz-milestone","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["STK","BK7506","PRU","BK7067","SMI","RMS.AU","WAF.AU","PRU.AU","ATH.AU","BK4585","BK7095","FFM.AU","PDI","BK4162","GMD.AU","PDI.AU","ASL.AU","NST.AU","SMI.AU","ATH","BK7104","STK.AU","BK4588"],"gpt_icon":0},{"id":"2526550996","title":"Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526550996","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526550996?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:35","pubTimestamp":1744284900,"startTime":"0","endTime":"0","summary":"– Clinically Meaningful Efficacy Observed on Multiple Assessments –。– Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions –。Type: Oral Presentation Title: Topline Data from a Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in Multiple System AtrophyPresenter: Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical CenterSummary: The oral presentation produced additional data on Alterity’s ATH434-201 Phase 2 clinical trial. Overall, the study results support continued advancement of ATH434 for the treatment of MSA. The imaging outcomes in n=61 participants indicate a heterogeneous localization of pathology and evidence that ATH434 reduces the iron signal in MSA affected brain regions. The clinical analysis included 71 patients who had at least one-post baseline UMSARS I assessment. The data showed that on the modified UMSARS I rating scale, ATH434 demonstrated a clinically significant treatment effect versu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-presents-encouraging-data-113500434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2211815571.USD","BK4143","MSA","LENZ","LU2125909759.SGD","AFG","LU2125909916.SGD","BK4107","LU1815336091.USD","BK4117","TUG","LU0728928796.USD","ATHE","BK4139","LU0053671581.USD","BK4007","BK4178","LU0757428866.USD","ATH.AU","LU1923622291.USD","AAN"],"gpt_icon":0},{"id":"2524144455","title":"Fidelity Spotlights 8-Year-Old Bullish Bitcoin Move From Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2524144455","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524144455?lang=en_us&edition=fundamental","pubTime":"2025-04-01 15:56","pubTimestamp":1743494160,"startTime":"0","endTime":"0","summary":"Fidelity Digital Asset’s post serves as a reminder of the rich history of Bitcoin and its resilience as the leading crypto asset.More importantly, it highlights how favorable regulation can drive adoption and price growth in the crypto space.Today, thanks to favorable regulation, Metaplanet continues its Bitcoin buying spree even withdebt funding. Due to its profitability, it recently issued $13.3 million worth of zero-interest bonds for future Bitcoin purchases.Some believe that if other major countries follow the Japanese model, Bitcoin’s value could easily overtake gold faster than projected by Jurrien Timmer of Fidelity Investment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/fidelity-spotlights-8-year-old-bullish-bitcoin-move-from-japan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["ATH","09042","03042","BTC.AU","03439","BTCmain","BTC","03008","ATH.AU","83042","BK4594","BK4162","BK7067","BTC.USD.CC","BK4601","BTC.USD.HKCC","09008","BK4588","BK1611","XBTmain","BK4585","09439"],"gpt_icon":1},{"id":"2522379016","title":"BRIEF-Alterity Therapeutics Completes Last Patient Visit In ATH434-202 Open-Label Phase 2 Trial In Multiple System Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2522379016","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522379016?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:34","pubTimestamp":1743075245,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Completes Last Patient Visit In ATH434-202 Open-Label Phase 2 Trial In Multiple System AtrophyMarch 27 (Reuters) - Alterity Therapeutics Ltd ATH.AX:ALTERITY THERAPEUTICS CO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA0LF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2522537950","title":"Alterity Therapeutics Ltd: Topline Data Expected Mid-Year 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537950","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537950?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:25","pubTimestamp":1743074719,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA0LF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2522379506","title":"Alterity Therapeutics Completes Last Patient Visit in Ath434-202 Open-Label Phase 2 Trial in Multiple System Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2522379506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522379506?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:25","pubTimestamp":1743074719,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA0LF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2522290362","title":"Alterity Completes Neurogenerative Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2522290362","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522290362?lang=en_us&edition=fundamental","pubTime":"2025-03-27 09:37","pubTimestamp":1743039442,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  completed the phase two trial of its drug candidate, ATH434, for patients with advanced multiple system atrophy, according to a Thursday Australian bourse filing.The company completed the last patient visit in the trial, finishing all clinical evaluations, the filing said.The company expects to report the data from the study in mid-2025, the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2520151660","title":"Justin Sun Reveals Rules of Making Memes on Tron: Details","url":"https://stock-news.laohu8.com/highlight/detail?id=2520151660","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520151660?lang=en_us&edition=fundamental","pubTime":"2025-03-19 11:42","pubTimestamp":1742355720,"startTime":"0","endTime":"0","summary":"Tron Founder Justin Sun has triggered new sentiment around meme coin creation on the layer-1 blockchain network. Taking to his official X account, Sunannounced what appears to be insurance for creator","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/justin-sun-reveals-rules-of-making-memes-on-tron-details","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["SOL","BK4162","SEC.AU","SOL.AU","BK7105","ATH","BK4129","ATH.AU","BK4519","BK7067","SOL.USD.HKCC","BK7083"],"gpt_icon":0},{"id":"2520384391","title":"XRP Flashes 102% Liquidation Imbalance as Price Rebound Fails","url":"https://stock-news.laohu8.com/highlight/detail?id=2520384391","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520384391?lang=en_us&edition=fundamental","pubTime":"2025-03-18 14:49","pubTimestamp":1742280540,"startTime":"0","endTime":"0","summary":"As reported by U.Today, the XRP price is predicted to soar as high as $3.47. This prediction relies on the higher band of the asset’s Bollinger Bands. If this plays out and XRP surges to this level, it could retest its all-time high  of $3.84, recorded seven years ago in 2018.Analysts, however, expect XRP to continue consolidating for a while before it can retest higher levels.Technical indicators show that it might face resistance at $2.54. If the altcoin multiplies the resistance to support, it could attempt $3.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/xrp-flashes-102-liquidation-imbalance-as-price-rebound-fails","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["ATH.AU","BK7067","BK4162","ATH"],"gpt_icon":0},{"id":"2519808923","title":"Coinbase to Remove Three Crypto Assets? Reason Behind It","url":"https://stock-news.laohu8.com/highlight/detail?id=2519808923","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519808923?lang=en_us&edition=fundamental","pubTime":"2025-03-13 15:50","pubTimestamp":1741852200,"startTime":"0","endTime":"0","summary":"Major cryptocurrency exchange Coinbase has announced its decision to delist three digital assets from its platform; meme coins Floki, GIGA and Turbo are affected in this latest cleanup. The move comes","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/coinbase-to-remove-three-crypto-assets-reason-behind-it","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["COIN","APT.USD.HKCC","BK4595","BK4516","GIGA","TON.USD.CC","BK7067","LU1861558580.USD","BK4112","BK4551","ATH.AU","BK4187","BK4596","BK4585","BK4554","BK4162","APT.USD.CC","BK4535","TON.USD.HKCC","BK4600","ATH","LU1861559042.SGD","BK4539","BK4588"],"gpt_icon":1},{"id":"2518081994","title":"3 Promising ASX Penny Stocks With Market Caps Over A$20M","url":"https://stock-news.laohu8.com/highlight/detail?id=2518081994","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518081994?lang=en_us&edition=fundamental","pubTime":"2025-03-12 10:05","pubTimestamp":1741745113,"startTime":"0","endTime":"0","summary":"As Australian shares brace for a potential downturn, with the ASX 200 futures indicating a significant drop, investors are keenly observing market movements and their implications. In such volatile times, penny stocks—though an older term—remain relevant as they often represent smaller or emerging companies that could offer value. By focusing on those with strong financials and growth potential, investors might uncover opportunities in these lesser-known stocks.Overview: Alterity Therapeutics Limited is an Australian company focused on researching and developing therapeutic drugs for neurological disorders such as Alzheimer’s, Huntington’s, and Parkinson’s diseases, with a market cap of A$54.91 million.Overview: Magmatic Resources Limited is involved in the development and exploration of mineral properties in Australia, with a market cap of A$21.27 million.Operations: Magmatic Resources Limited has not reported any specific revenue segments.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-promising-asx-penny-stocks-020513943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7062","BK7095","VMT.AU","XJO.AU","ATH.AU","MAG.AU","IGL.AU","GTN.AU","XAO.AU","BK7045","BK7506","BK7048","XKO.AU","CLX.AU","AX1.AU","BK7104","GNG.AU","BK7018","BK7067","EZZ.AU","ATHE","BK7021","RPL.AU","BK7055","BIS.AU","SHA.AU","BK7058","WAF.AU","BK7129"],"gpt_icon":0},{"id":"2514336316","title":"BRIEF-Alterity Therapeutics Posts HY Net Loss After Tax Attributable A$7.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514336316","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514336316?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:11","pubTimestamp":1740705070,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Posts HY Net Loss After Tax Attributable A$7.2 MillionFeb 28 (Reuters) - Alterity Therapeutics Ltd ATH.AX:HY NET LOSS AFTER TAX ATTRIBUTABLE A$7.2 MILLIONFurther company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2514363131","title":"Alterity Therapeutics - Hy Net Loss After Tax Attributable a$7.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514363131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514363131?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:10","pubTimestamp":1740705046,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2513792579","title":"Alterity Therapeutics Ltd-Proposed Issue of Securities - Ath","url":"https://stock-news.laohu8.com/highlight/detail?id=2513792579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513792579?lang=en_us&edition=fundamental","pubTime":"2025-02-24 13:07","pubTimestamp":1740373635,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUE28YFHZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2510826250","title":"Alterity Therapeutics Raises AU$40 Million via Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510826250","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510826250?lang=en_us&edition=fundamental","pubTime":"2025-02-11 13:05","pubTimestamp":1739250305,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ASX:ATH) is set to raise AU$40 million via a two-tranche placement at AU$0.011 apiece, according to a Monday Australian bourse filing.The first tranche of the placement is to ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATH.AU","BK7067","LENZ","BK4139"],"gpt_icon":0},{"id":"2510560738","title":"Alterity Therapeutics Raises a$40.0 Million in Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510560738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510560738?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:25","pubTimestamp":1739190300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA6LZFT2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2510395859","title":"Alterity Therapeutics Ltd - Proceeds to Fund Ongoing Clinical Development for Ath434","url":"https://stock-news.laohu8.com/highlight/detail?id=2510395859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510395859?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:25","pubTimestamp":1739190300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA6LZFT2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2510705380","title":"BUZZ-Australia's Alterity Therapeutics falls on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510705380","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510705380?lang=en_us&edition=fundamental","pubTime":"2025-02-10 10:05","pubTimestamp":1739153104,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Alterity Therapeutics falls on discounted placement** Shares of Australia's Alterity Therapeutics ATH.AX fall as much as 8.3% to A$0.011, on track for a third consecutive session of decline** Stock hits its lowest level since Jan. 31** Biotechnology co raises A$40.0 mln  in a placement at an issue price of A$0.011 per share** Issue price represents a discount of 8.3% to stock's last close** Co says funds will be used primarily to advance development of ATH434, a small molecule drug candidate for Parkinsonian disorders** Stock up 43.8% this year, as of 0159 GMT  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nL4N3P105B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2510074336","title":"BRIEF-Alterity Therapeutics Raises A$40M To Advance Ath434 Development In MSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2510074336","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510074336?lang=en_us&edition=fundamental","pubTime":"2025-02-10 09:17","pubTimestamp":1739150223,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Raises A$40M To Advance Ath434 Development In MSAFeb 10  - Alterity Therapeutics Ltd ATH.AX:ALTERITY RAISES A$40M TO ADVANCE ATH434 DEVELOPMENT IN MSAPLACEMENT WAS CONDUCTED AT A$0.011 PER SHAREFurther company coverage: ATH.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3OY2CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2510736580","title":"Alterity Therapeutics - Alterity Raises a$40M to Advance Ath434 Development in MSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2510736580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510736580?lang=en_us&edition=fundamental","pubTime":"2025-02-10 07:23","pubTimestamp":1739143432,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250209:nFWN3OY2CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":62,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATH.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATH.AU\",market:\"AU\",,,undefined,":[]}}